ThinkSabio

$PPCB

$1.95▲ +6.0% YTD

12 SEC 13D/G filings tracked · Last updated Nov 2, 2026

Filing History
News
PPCB ▲ +6.0% - Propanc Biopharma, Inc.
CP $1.95▲ +6.0%Nov 2, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-? Inhibitor on TGF-? Pathway in Pancreatic Cancer…

News
PPCB ▼ -3.8% - Propanc Biopharma, Inc.
CP $2.03▲ -3.8%Oct 30, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Pati…

News
PPCB ▲ +4.1% - Propanc Biopharma, Inc.
CP $2.53▲ +4.1%Oct 28, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients…

News
PPCB ▼ -3.6% - Propanc Biopharma, Inc.
CP $0.27▲ -3.6%Oct 26, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability…

News
PPCB ▼ -15.6% - Propanc Biopharma, Inc.
CP $0.27▲ -15.6%Oct 22, 2026 · ThinkSabio Blog

$PPCB - CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans…

News
PPCB ▼ -6.3% - Propanc Biopharma, Inc.
CP $0.30▲ -6.3%Oct 22, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans…

News
PPCB ▲ +5.9% - Propanc Biopharma, Inc.
CP $0.36▲ +5.9%Oct 16, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells…

News
PPCB ▲ +2.4% - Propanc Biopharma, Inc.
CP $0.42▲ +2.4%Oct 14, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pan…

News
PPCB ▲ +2.0% - Propanc Biopharma, Inc.
CP $0.50▲ +2.0%Oct 7, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution M…

News
PPCB ▲ +7.9% - Propanc Biopharma, Inc.
CP $0.68▲ +7.9%Sep 22, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015…

News
PPCB ▼ -1.0% - Propanc Biopharma, Inc.
CP $1.00▲ -1.0%Sep 9, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027…

News
PPCB ▲ +177.6% - Propanc Biopharma, Inc.
CP 2.97▲ +177.6%Aug 27, 2026 · ThinkSabio Blog

$PPCB Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Surviva…